首页|期刊导航|湖北科技学院学报(医学版)|基于代谢组学与FXR/NLRP3通路的分析探讨糖尿病大鼠肝脏代谢紊乱的机制

基于代谢组学与FXR/NLRP3通路的分析探讨糖尿病大鼠肝脏代谢紊乱的机制OA

Investigating the Mechanisms of Hepatic Metabolic Disturbances in Diabetic Rats Based on Metabolomics and the FXR/NLR P3 Pathway

中文摘要英文摘要

目的 通过构建链脲佐菌素(STZ)联合高脂饮食糖尿病大鼠模型,比较模型组与正常组大鼠肝脏生化指标、病理特征、差异代谢物及关键蛋白表达,筛选糖尿病相关肝脏特异性代谢标志物,解析肝代谢紊乱机制,为治疗靶点挖掘提供依据.方法 将 10 只 SPF 雄性 Wistar大鼠随机分为空白(Control)组和模型(Model)组,每组5 只.Model 组给予链脲佐菌素(STZ)注射联合高脂饮食构建模型,喂养6 周后,检测两组大鼠空腹 8h 血糖(FBG)、肝脏谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆固醇(TC)、甘油三酯(TG)、超氧化物歧化酶(SOD)、丙二醛(MDA)、谷胱甘肽(GSH)指标,苏木素-伊红(HE)染色观察肝组织病理变化,非靶向代谢组学筛选肝脏差异代谢物并富集通路,最后采用蛋白免疫印迹检测肝脏法尼醇 X 受体(FXR)、NOD 样受体热蛋白结构域相关蛋白3(NLRP3)、核因子 κB(NF-κB)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、半胱天冬酶-1(Caspase-1)等蛋白表达.结果 与 Control 组相比,Model 组的 FBG 值显著升高(P<0.01)、Model 组大鼠肝脏出现病理损伤,肝脏 ALT、AST、TC、TG 显著升高(P<0.01),GSH、SOD 显著下降,MDA 显著升高(P<0.01),FXR蛋白表达显著下降,伴随着炎症相关因子蛋白显著升高,差异有统计学意义.肝脏代谢组学发现22 个差异代谢物(牛磺酸、谷氨酸较为典型),核心通路涉及牛磺酸和亚牛磺酸代谢途径与丙氨酸、天冬氨酸和谷氨酸代谢、淀粉和蔗糖代谢、甘油磷脂代谢,且 Model 组亚牛磺酸代谢物显著减少、谷氨酸显著增加(P均<0.05).结论 糖尿病模型大鼠与正常大鼠肝脏差异明确,FXR/NLRP3 或通过调控牛磺酸-亚牛磺酸、丙氨酸-天冬氨酸-谷氨酸代谢影响内分泌稳态,参与糖尿病发生发展.此结果为揭示糖尿病肝脏代谢紊乱机制、筛选特异性代谢标志物及挖掘治疗靶点提供实验依据.

Objective By establishing a streptozotocin(STZ)-induced diabetic rat model combined with a high-fat diet,this study aimed to compare the biochemical indicators,pathological features,differential metabolites,and key protein expressions in the liver between the model group and the normal group.The goal was to screen for diabetes-associated liver-specific metabolic biomarkers and elucidate the mechanisms underlying hepatic metabolic dysfunction,thereby providing a basis for the identification of therapeutic targets.Methods Ten SPF male wistar rats were randomly divided into a blank(Control)group and a model(Model)group,with five rats in each group.The Model group was given STZ injection combined with a high-fat diet to establish the model.After 6 weeks of feeding,the following parameters were measured in both groups following an 8-hour fasting period:fasting blood glucose(FBG),liver alanine aminotransferase(ALT),aspar-tate aminotransferase(AST),total cholesterol(TC),triglycerides(TG),superoxide dismutase(SOD),malondialdehyde(MDA),and glu-tathione(GSH).Hematoxylin-eosin(HE)staining was used to observe the pathological changes in liver tissues.Non-targeted metabolomics was employed to screen for differential metabolites in the liver and identify enriched metabolic pathways.Finally,Western blotting was used to detect the protein expression levels of farnesoid X receptor(FXR),NOD-like receptor pyrin domain-containing protein 3(NLRP3),nu-clear factor κB(NF-κB),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),and caspase-1.Results Compared with the Control group,the FBG value in the Model group was significantly increased(P<0.01).The Model group rats exhibited pathological liver injury,with significantly increased ALT,AST,TC,and TG(P<0.01),and significantly decreased GSH and SOD and increased MDA(P<0.01).The expression of FXR protein was significantly decreased,accompanied by a significant upregulation of inflammatory-related factor proteins.These differences were statistically significant.Liver metabolomics analysis identified 22 differential metabolites(with taurine and glutamic acid being particularly representative).The core metabolic pathways involved included taurine and hypotaurine metabolism,alanine,aspar-tate,and glutamate metabolism,starch and sucrose metabolism,and glycerophospholipid metabolism.The Model group showed a significant reduction in hypotaurine metabolites and a significant increase in glutamic acid(P<0.05).Conclusion Distinct differences were observed between the livers of diabetic model rats and normal rats.The FXR/NLRP3 pathway may influence endocrine homeostasis—and thereby par-ticipate in the pathogenesis and progression of diabetes—by regulating taurine-hypotaurine and alanine-aspartate-glutamate metabolism.These findings provide an experimental basis for elucidating the mechanisms underlying hepatic metabolic dysfunction in diabetes,identifying specific metabolic biomarkers,and discovering potential therapeutic targets.

姚子印;胡倩宇;李芳;尧青;周苗;张丹丹

湖北科技学院医学部药学院糖尿病心脑血管病变省级重点实验室,湖北 咸宁 437100湖北科技学院医学部药学院糖尿病心脑血管病变省级重点实验室,湖北 咸宁 437100湖北科技学院医学部药学院糖尿病心脑血管病变省级重点实验室,湖北 咸宁 437100湖北科技学院医学部药学院糖尿病心脑血管病变省级重点实验室,湖北 咸宁 437100天门市中医医院湖北科技学院医学部药学院糖尿病心脑血管病变省级重点实验室,湖北 咸宁 437100

医药卫生

糖尿病肝脏代谢非靶向代谢组学FXR/NLRP3

DiabetesLiver metabolismUntargeted metabolomicsFXR/NLRP3

《湖北科技学院学报(医学版)》 2026 (3)

227-233,7

湖北省自然科学基金创新发展联合基金项目(2026AFC0526)咸宁市自然科学基金"大健康专项"项目(2025DJK06)中药资源与中药化学湖北省重点实验室开放基金(KLRCCM2305)

10.16751/j.cnki.2095-4646.2025111902

评论